AbbVie Deutschland GmbH & Co. KG — Sponsor Intelligence | 138 EU Trials

Filter these 138 trials by condition, phase, country and more.

Open in Search →

138 Registered trials

54 Recruiting

81 Completed trials

25 Countries active

105 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 58 Phase II/III: 6 Phase II: 31 Phase I/II: 8 Phase III/IV: 5 Phase IV: 2 Phase I: 13 Phase I (Other): 12 Phase I (FiH): 2 Other: 1

Oversight events:

2 serious breaches 16 temporary halts 14 corrective measures across 15 trials

View oversight register →

100%

81 of 81 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Fallopian tube cancer 5 Non-small cell lung cancer 5 Dermatitis atopic 5 Colitis ulcerative 5 Crohn's disease 5 Migraine without aura 5 Migraine with aura 5 Ovarian epithelial cancer 5 Diffuse large B-cell lymphoma 3 Colorectal cancer 3 Migraine 3 Neovascular age-related macular degeneration 3

Top IMPs

UPADACITINIB 20 RISANKIZUMAB 15 VENETOCLAX 13 TELISOTUZUMAB ADIZUTECAN 9 BUDIGALIMAB 8 ATOGEPANT 7 EPCORITAMAB 6 ADALIMUMAB 5 LIVMONIPLIMAB 5 LUTIKIZUMAB 5 MIRVETUXIMAB SORAVTANSINE 5 PREDNISOLONE ACETATE 5

All trials — page 6

138 total

Multicenter, Phase 3 Study of Venetoclax and Azacitidine as Maintenance Therapy for Patients with Acute Myeloid Leukemia in First Remission … Ended

2023-507221-42-00 Phase III 7 countries AZACITIDINE; VENETOCLAX
Evaluation of upadacitinib in adult subjects with axial spondyloarthritis Ended

2022-501018-78-00 Phase III 9 countries ABT-494
A Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax alone or in Combination with Ruxolitinib in Subjects with Myelofibrosi… Ended

2023-507276-53-00 Phase II 4 countries NAVITOCLAX
An Extension Trial to Evaluate the Long-term Safety and Efficacy of Bimatoprost SR in Patients with Open Angle Glaucoma or Ocular Hypertensi… Ended

2023-504601-36-00 Phase III 4 countries BIMATOPROST
A Phase 3b Study to Evaluate the Duration of Effect of Bimatoprost SR in Participants with Open-Angle Glaucoma or Ocular Hypertension Ended

2022-502380-37-00 Phase III 7 countries BIMATOPROST
A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis. Ended

2023-505476-29-00 Phase III 10 countries PREDNISOLONE; UPADACITINIB
Phase 1/2 Dose Finding, Safety and Efficacy Study of Ibrutinib in Pediatric Subjects with Chronic Graft Versus Host Disease (cGVHD) Ended

2023-507330-24-00 Phase I/II 5 countries IBRUTINIB; PREDNISONE
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema) – Measure Up 2 Ended

2022-502936-38-00 Phase III 15 countries UPADACITINIB
Evaluation of Upadacitinib in Adolescent and Adult Patients with Moderate to Severe Atopic Dermatitis (Eczema)– Measure Up 1 Ended

2022-502938-30-00 Phase III 9 countries UPADACITINIB
A Study of Venetoclax Co-Administered with Low Dose Cytarabine Versus Low Dose Cytarabine in Untreated Patients with Acute Myeloid Leukemia … Ended

2024-513630-37-00 Phase III 1 country CYTARABINE; VENETOCLAX
A Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in previously untreated Subjects with Acute Myeloid Leukemia who ar… Ended

2024-513631-25-00 Phase III 6 countries VENETOCLAX
A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym… Ended

2023-507271-21-00 Phase III 11 countries IBRUTINIB
A Study Evaluating Venetoclax in Combination With Azacitidine in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndromes (MD… Ended

2023-507154-32-00 Phase I 2 countries
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants Wi… Ended

2024-510727-19-00 Phase II 6 countries UPADACITINIB
A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped… Ended

2023-504711-32-00 Phase III 2 countries ADALIMUMAB
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended

2022-500691-59-00 Phase II 3 countries FLORQUINITAU (18F); HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST N-TERMINALLY TRUN…
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Partici… Ended

2024-512586-13-00 Phase I 3 countries
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONS… Ended

2024-512804-20-00 Phase III 6 countries TELISOTUZUMAB ADIZUTECAN; TRIFLURIDINE, TIPIRACIL HYDROCHLORIDE

Showing 121–138 of 138 trials

← All sponsors A–Z